Arcus Biosciences In Collaboration With Gilead Sciences, Completes Patient Enrollment In Phase 3 Trial Evaluating A Domvanalimab-Containing Regimen In First-Line Metastatic Upper GI Cancers
Portfolio Pulse from Benzinga Newsdesk
Arcus Biosciences, in collaboration with Gilead Sciences, has completed patient enrollment for a Phase 3 trial evaluating a domvanalimab-containing regimen for first-line metastatic upper GI cancers. Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas, potentially making it first-to-market for this patient population.
June 10, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences, in collaboration with Arcus Biosciences, has completed patient enrollment for a Phase 3 trial of domvanalimab. This collaboration could enhance Gilead's oncology portfolio if the trial is successful.
Gilead Sciences' collaboration with Arcus Biosciences on the Phase 3 trial of domvanalimab could strengthen its oncology portfolio. Successful trial results could positively impact Gilead's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 70
POSITIVE IMPACT
Arcus Biosciences has completed patient enrollment for a Phase 3 trial of domvanalimab in collaboration with Gilead Sciences. This milestone could position domvanalimab as the first-to-market anti-TIGIT antibody for upper GI adenocarcinomas.
The completion of patient enrollment in a Phase 3 trial is a significant milestone. If successful, domvanalimab could be the first-to-market anti-TIGIT antibody for upper GI adenocarcinomas, potentially driving up Arcus Biosciences' stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100